Pharmaceutical

EC approves AstraZeneca’s Fasenra for EGPA treatment

The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.

Oct 30, 2024 - 04:00
EC approves AstraZeneca’s Fasenra for EGPA treatment
The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.
Read the original article

Tags:

Previous Article

US Border Protection warns pharma of risks with incorrect biologic importation

Next Article

South Korean pricing reform suggests more flexible drug reimbursement negotiations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS and 2seventy bio’s Abecma gains approval for multiple myeloma

BMS and 2seventy bio’s Abecma gains approval for multip...

Apr 9, 2024

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024

STAT+: Targeted drug greatly slows progression of a brain cancer

STAT+: Targeted drug greatly slows progression of a bra...

Jun 4, 2023